Literature DB >> 34908211

Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data.

Julie M Paik1,2,3,4, Elisabetta Patorno1,4, Min Zhuo1,2,4,5, Lily G Bessette1, Cassandra York1, Nileesa Gautam1, Dae Hyun Kim1,4,6,7, Seoyoung C Kim1,4,8.   

Abstract

BACKGROUND: Prior validation studies of claims-based definitions of chronic kidney disease (CKD) using ICD-9 codes reported overall low sensitivity, high specificity, and variable but reasonable PPV. No studies to date have evaluated the accuracy of ICD-10 codes to identify a US patient population with CKD.
METHODS: We assessed the accuracy of claims-based algorithms to identify adults with CKD Stages 3-5 compared with laboratory values in a subset (~40%) of a US commercial insurance claims database (Optum's de-identified Clinformatics® Data Mart Database). We calculated the positive predictive value (PPV) of one or two ICD-9 (2012-2014) or ICD-10 (2016-2018) codes for CKD compared with a lab-based estimated glomerular filtration rate (eGFR) occurring within prespecified windows (±90 days, ±180 days, ±365 days) of the ICD-based CKD code(s).
RESULTS: The study population ranged between 104 774 and 161 305 patients (ICD-9 cohorts) and between 285 520 and 373 220 patients (ICD-10 cohorts). The mean age was 74.4 years (ICD-9) and 75.6 years (ICD-10) and the median eGFR was 48 ml/min/1.73 m2 . The algorithm of two CKD codes compared with a lab value ±90 days of the first code achieved the highest PPV (PPV 86.36% [ICD-9] and 86.07% [ICD-10]). Overall, ICD-10 based codes had comparable PPVs to ICD-9 based codes and all ICD-10 based algorithms had PPVs >80%. The algorithm of one CKD code compared with laboratory value ±180 days maintained the PPV above 80% but still retained a large number of patients (PPV 80.32% [ICD-9] and 81.56% [ICD-10]).
CONCLUSION: An ICD-10-based definition of CKD identified with sufficient accuracy a patient population with CKD Stages 3-5. Our findings suggest that claims databases could be used for future real-world research studies in patients with CKD Stages 3-5.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  chronic kidney disease; claims data; validation study

Mesh:

Year:  2021        PMID: 34908211      PMCID: PMC8917076          DOI: 10.1002/pds.5398

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  30 in total

Review 1.  Developments in post-marketing comparative effectiveness research.

Authors:  S Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2007-06-06       Impact factor: 6.875

Review 2.  Chronic kidney disease.

Authors:  Andrew S Levey; Josef Coresh
Journal:  Lancet       Date:  2011-08-15       Impact factor: 79.321

3.  Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness.

Authors:  Jacqueline Corrigan-Curay; Leonard Sacks; Janet Woodcock
Journal:  JAMA       Date:  2018-09-04       Impact factor: 56.272

4.  Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects.

Authors:  George R Bailie; George Eisele; Lei Liu; Erik Roys; Margaret Kiser; Frederick Finkelstein; Robert Wolfe; Friedrich Port; Sally Burrows-Hudson; Rajiv Saran
Journal:  Nephrol Dial Transplant       Date:  2005-03-15       Impact factor: 5.992

5.  Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.

Authors:  Andrew S Levey; Josef Coresh; Tom Greene; Lesley A Stevens; Yaping Lucy Zhang; Stephen Hendriksen; John W Kusek; Frederick Van Lente
Journal:  Ann Intern Med       Date:  2006-08-15       Impact factor: 25.391

6.  Risk profile, quality of life and care of patients with moderate and advanced CKD: The French CKD-REIN Cohort Study.

Authors:  Bénédicte Stengel; Marie Metzger; Christian Combe; Christian Jacquelinet; Serge Briançon; Carole Ayav; Denis Fouque; Maurice Laville; Luc Frimat; Christophe Pascal; Yves-Edouard Herpe; Pascal Morel; Jean-François Deleuze; Joost P Schanstra; Céline Lange; Karine Legrand; Elodie Speyer; Sophie Liabeuf; Bruce M Robinson; Ziad A Massy
Journal:  Nephrol Dial Transplant       Date:  2019-02-01       Impact factor: 5.992

7.  Detecting chronic kidney disease in population-based administrative databases using an algorithm of hospital encounter and physician claim codes.

Authors:  Jamie L Fleet; Stephanie N Dixon; Salimah Z Shariff; Robert R Quinn; Danielle M Nash; Ziv Harel; Amit X Garg
Journal:  BMC Nephrol       Date:  2013-04-05       Impact factor: 2.388

8.  Electronic problem list documentation of chronic kidney disease and quality of care.

Authors:  Lipika Samal; Jeffrey A Linder; David W Bates; Adam Wright
Journal:  BMC Nephrol       Date:  2014-05-04       Impact factor: 2.388

9.  Surveillance of CKD epidemiology in the US - a joint analysis of NHANES and KEEP.

Authors:  O B Myers; V S Pankratz; K C Norris; J A Vassalotti; M L Unruh; C Argyropoulos
Journal:  Sci Rep       Date:  2018-10-26       Impact factor: 4.379

10.  Comparison of the Complexity of Patients Seen by Different Medical Subspecialists in a Universal Health Care System.

Authors:  Marcello Tonelli; Natasha Wiebe; Braden J Manns; Scott W Klarenbach; Matthew T James; Pietro Ravani; Neesh Pannu; Jonathan Himmelfarb; Brenda R Hemmelgarn
Journal:  JAMA Netw Open       Date:  2018-11-02
View more
  2 in total

1.  Clinical characteristics and disease outcomes in non-diabetic chronic kidney disease: retrospective analysis of a US healthcare claims database.

Authors:  Christoph Wanner; Johannes Schuchhardt; Chris Bauer; Stefanie Lindemann; Meike Brinker; Sheldon X Kong; Frank Kleinjung; Andrea Horvat-Broecker; Tatsiana Vaitsiakhovich
Journal:  J Nephrol       Date:  2022-05-14       Impact factor: 3.902

2.  Validation of a Classification Algorithm for Chronic Kidney Disease Based on Health Information Systems.

Authors:  Pietro Manuel Ferraro; Nera Agabiti; Laura Angelici; Silvia Cascini; Anna Maria Bargagli; Marina Davoli; Giovanni Gambaro; Claudia Marino
Journal:  J Clin Med       Date:  2022-05-11       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.